Education
About Us
Working with TipRanks
Follow Us
Crescent Biopharma (CBIO)
NASDAQ:CBIO
CBIO Stock Chart & Stats
$9.59
--
Market closed
$9.59
--
Day’s Range― - ―
52-Week Range$9.43 - $37.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)145.41K
Market Cap
$264.27M
Enterprise Value$1.71M
Total Cash (Recent Filing)$133.26M
Total Debt (Recent Filing)$1.74M
Price to Earnings (P/E)―
Beta0.94
Next Earnings
Apr 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.27
Shares Outstanding27,556,767
10 Day Avg. Volume163,515
30 Day Avg. Volume145,412
Financial Highlights & Ratios
PEG Ratio-13.03
Price to Book (P/B)-103.72
Price to Sales (P/S)0.00
P/FCF Ratio-51.61
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.03
Forecast
1Y Price Target
$30.14Price Target Upside214.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Preclinical DifferentiationPreclinical results demonstrating cooperative binding and enhanced T-cell activation for CR-001 support its differentiated mechanism versus competing VEGF x PD-(L)1 formats and suggest potential for meaningful anti-tumor activity in clinical studies.
Regulatory ClearanceUS FDA IND clearance for CR-001 enables initiation of clinical testing for a PD-1 x VEGF bispecific, creating a clear pathway to generate human proof-of-concept data that could materially de-risk the program.
Strategic Partnership And Territorial RightsPartnership and cross-licensing with Kelun grants Crescent Biopharma ex-Greater China development rights and supports parallel trial generation, improving chances for faster global data readouts and regional commercialization options.
Bears Say
Clinical Development RiskEarly-stage status of CR-001 and ADC programs means clinical proof of benefit is required before therapeutic and commercial potential can be confirmed, exposing the stock to significant execution risk if trials fail to meet endpoints.
Financial PerformanceA reported net loss underscores current financial strain and may force prioritization of programs or reliance on partnerships, potentially slowing independent development progress.
Financing And Dilution RiskHigh cash burn and a limited cash runway increase the likelihood of needing additional financing, which could dilute existing shareholders and disrupt planned development timelines.
Crescent Biopharma News
CBIO FAQ
What was Crescent Biopharma’s price range in the past 12 months?
Crescent Biopharma lowest stock price was $9.43 and its highest was $37.00 in the past 12 months.
What is Crescent Biopharma’s market cap?
Crescent Biopharma’s market cap is $264.27M.
When is Crescent Biopharma’s upcoming earnings report date?
Crescent Biopharma’s upcoming earnings report date is Apr 30, 2026 which is in 87 days.
How were Crescent Biopharma’s earnings last quarter?
Crescent Biopharma released its earnings results on Nov 06, 2025. The company reported -$1.27 earnings per share for the quarter, beating the consensus estimate of -$1.959 by $0.689.
Is Crescent Biopharma overvalued?
According to Wall Street analysts Crescent Biopharma’s price is currently Undervalued.
Does Crescent Biopharma pay dividends?
Crescent Biopharma pays a Quarterly dividend of $0.24 which represents an annual dividend yield of N/A. See more information on Crescent Biopharma dividends here
What is Crescent Biopharma’s EPS estimate?
Crescent Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Crescent Biopharma have?
Crescent Biopharma has 27,556,767 shares outstanding.
What happened to Crescent Biopharma’s price movement after its last earnings report?
Crescent Biopharma reported an EPS of -$1.27 in its last earnings report, beating expectations of -$1.959. Following the earnings report the stock price went up 5.39%.
Which hedge fund is a major shareholder of Crescent Biopharma?
Currently, no hedge funds are holding shares in CBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Crescent Biopharma Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$30.14 (214.29% Upside)
$30.14 (214.29% Upside)
Insider Transactions
Bought Shares
Worth $18.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 5.6%
Last 30 Days ▼ 1.5%
Last 30 Days ▼ 1.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-20.89%
12-Months-Change
Fundamentals
Return on Equity
-51.70%
Trailing 12-Months
Asset Growth
544.72%
Trailing 12-Months
Company Description
Crescent Biopharma
Crescent Biopharma, Inc., an oncology company, develops therapies for cancer patients. Its pipeline includes a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates to treat solid tumors. The company is headquartered in Waltham, Massachusetts.
CBIO Stock 12 Month Forecast
Average Price Target
$30.14
▲(214.29% Upside)
Technical Analysis
Compugen
―
Fate Therapeutics
―
Orchestra BioMed Holdings
―
Fractyl Health, Inc.
―
Actuate Therapeutics, Inc.
―